Filter
Exclude
Time range
-
Near
Book a 3 day #EPPC26 for access to 100 #PowerApps, #CopilotStudio, #PowerPages, #ALM, #LowCode, #PowerAutomate, #PowerPlatform, #AI, #Copilot and more expert-led sessions. Don't wait any longer. Power up your Microsoft Power Platform skills and network at EPPC, Copenhagen. espc.tech/conference/eppc-20…
10
Ethics and Public Policy Center retweeted
Terrific conference taking place in the Chicago area this weekend, featuring author and commentator @MZHemingway, EPPC President @RyanTAnd, and @ADFLegal's Erin Hawley. It's held on the campus of Concordia University in River Forest. Details below. issuesetc.org/2026conference…
1
5
19
1,477
Sonia Camina retweeted
We are back with CIMP Student Grants We are offering grants to support student attendance at: 🇩🇪 EPPC 2026 (Münster) €150 🇦🇷 SAPP & AASP–TPS 2026 (Trelew) €100 ✅ Open to students in Palaeozoic palynology 📩 Check how to apply: cimp.weebly.com/ #Palynology #Paleozoic
1
2
110
🏆❤️ Tonight, I was honored to receive a 2026 Prevention Impact Award and a 2026 Coalition Commitment Award from the East Providence Prevention Coalition (EPPC). I was also proud to accept a Partners in Prevention Award on behalf of the East Providence School Committee.
1
4
Research from the Ethics and Public Policy Center (EPPC) revealed that 1 in 10 women experience a serious adverse event after using the abortion pill mifepristone—22 times the rate the FDA currently acknowledges. We are pleased the FDA has taken our work seriously and decided to conduct a review of the safety of this drug. If its review is rigorous and thorough, we are confident the FDA will find results similar to our own.
14
23
3,020
BREAKING: The FDA will finally launch a proper investigation of the dangerous abortion pill. The dangerous abortion drug has killed multiple women, injured hundreds of thousands and killed millions of babies. The study, which is expected to take about six months with results anticipated after the midterm elections. A new analysis shows the pill has injured more than 95,000 women, at least. A study by the Ethics & Public Policy Center (EPPC), based on an examination of more than 865,000 insurance claims for mifepristone patients, found a serious adverse-event rate of approximately 11 percent — far higher than the FDA’s long-standing claim of less than 0.5 percent based on limited clinical trials. The EPPC data, filed in an amicus brief in the ongoing lawsuit State of Louisiana v. FDA, showed the rate of serious complications rose from 10.15 percent to 11.5 percent after the FDA eliminated the in-person dispensing requirement. “The rate of serious adverse events was significantly higher when the FDA’s in-person dispensing requirement was not in effect,” the EPPC brief stated. “Indeed, the data indicates that a serious adverse event was from 1.53 to 2.33 times as likely with remote dispensing as with in-person dispensing.” The analysis also revealed that the incidence of ectopic pregnancies — a life-threatening condition the abortion pill does not treat — was three to six times higher when the in-person visit requirement was dropped. Without an ultrasound or physical exam, women with ectopic pregnancies may mistake symptoms such as pain, cramping and bleeding for normal side effects of the abortion drug, potentially delaying emergency care. If such women take the abortion pill they could die. The findings add urgency to long-standing pro-life criticism of the FDA’s successive loosening of safeguards on mifepristone. The abortion pill should be banned. But at minimum mail-order abortions should stop and safety regulations put in place.
5
104
190
3,873